Patrick John Finn, an officer of Twist Bioscience Corp, filed a Form 144 notice on November 16, 2026, proposing the sale of 12,752 shares of common stock on NASDAQ with an aggregate market value of $1,322,234.48.
Key Highlights
- Proposed sale: 12,752 shares of Twist Bioscience Corp common stock, with an aggregate market value of $1,322,234.48, according to the filing.
- Acquisition source: The shares were acquired on November 12, 2026, through a restricted stock vesting event, classified as compensation from the issuer.
- Tax-related purpose: The filing states the sale "includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution."
- Shares outstanding: The filing reports 62,707,424 shares of common stock outstanding at the time of notice.
- Prior three-month sales: Patrick Finn sold a total of 112,925 shares in five separate transactions between August 18, 2026, and November 3, 2026, generating gross proceeds across those sales.
- Broker: The proposed sale is to be executed through Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, RI 02917.
Twist Bioscience Officer Patrick Finn Proposes Restricted Stock Sale Following November 2026 Vesting
According to the Form 144 notice filed on November 16, 2026, Patrick John Finn, identified as an officer of Twist Bioscience Corp (NASDAQ:TWST), intends to sell 12,752 shares of the company's common stock. The aggregate market value of the proposed sale is listed as $1,322,234.48 in the filing. The approximate date of sale is noted as November 16, 2026, and the designated exchange is NASDAQ.
The filing discloses that the 12,752 shares to be sold were acquired on November 12, 2026, through a restricted stock vesting event, with the issuer, Twist Bioscience Corp, identified as the person from whom the shares were acquired. The nature of payment is described as "Compensation." A remark in the filing states that the sale "includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution."
The filing also details prior sales of Twist Bioscience common stock by Patrick Finn during the preceding three months. Those transactions occurred on August 18, 2026 (78,355 shares, gross proceeds of $9,217,606.64), August 21, 2026 (4,046 shares, $562,662.66), October 2, 2026 (25,714 shares, $4,856,958.03), October 23, 2026 (2,245 shares, $302,153.21), and November 3, 2026 (2,565 shares, $347,305.36), as reported in the filing. The notice was signed by Joshua Schmitt as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Patrick Finn.
What Was Disclosed
Twist Bioscience Corp officer Patrick John Finn filed a Form 144 notice proposing to sell 12,752 shares of common stock valued at $1,322,234.48, acquired via restricted stock vesting on November 12, 2026, with the stated purpose including coverage of a tax obligation.



Please wait processing your request...